Aignostics Expands the Breadth and Depth of Spatial H&E Analysis in HETA

Ryan Sargent
November 18, 2026

We're excited to announce the latest update to HETA, our core platform for spatial H&E analysis. Highlights include immune phenotyping readouts, tumor-infiltrating lymphocyte (TIL) analysis, mitosis detection, and nerve and fat segmentation. With this update, HETA strengthens its position as one of the most comprehensive platforms for H&E analysis in both feature breadth and spatial depth. Two examples of how these new features can apply to clinical development:

  • Patient selection and enrollment: Immune phenotyping quantifies how far immune cells infiltrate the tumor core, to support selection of likely responders to checkpoint inhibitors.
  • Prognostic stratification: TILs and mitotic activity capture two established prognostic factors, the immune response and tumor proliferation. Nerve and fat segmentation map two tissues where tumor invasion is linked to prognosis.

Patient Selection and Enrollment: Identifying Likely Responders to Checkpoint Inhibitors

Response to checkpoint inhibitors is shaped by both the number of immune cells in a tumor and where they are located. HETA now measures both of these features through new immune phenotyping readouts, and extends its existing detection of tertiary lymphoid structures (TLS) with maturity stats.

  • Immune phenotyping: New readouts measure lymphocyte density in the tumor core and at its margins, each ranked against a pan-cancer TCGA reference to show whether immune infiltration is high or low relative to other tumors. Because HETA reports continuous values rather than a single label per slide, researchers can define their own inflamed, excluded, and desert thresholds.
  • TLS maturity: New readouts add counts and densities of mature and immature TLS, which show how organized the immune response is.
Side-by-side comparison of tumor zone (left) and lymphocyte cell classification over tissue segmentation (right) on the same H&E slide. HETA’s new readouts quantify lymphocyte density within each tumor zone and tissue compartment. Researchers can use them for spatial TIL analysis and to define their own inflamed, excluded, and desert thresholds.

Prognostic Stratification: Quantifying Immune Infiltration and Tumor Proliferation

Prognostic factors indicate how likely a tumor is to progress and help research teams build balanced trial cohorts. HETA now quantifies two new prognostic factors, TILs and mitotic activity, and adds nerve and fat segmentation as the basis for a third.

  • TILs: Among the most established prognostic markers for H&E, TILs reflect the strength of the immune response to the tumor. HETA measures lymphocyte density in tumor stroma and carcinoma, the ratio between them, and a combined score for the tumor core and invasive margin.
  • Mitotic activity: A direct measure of how fast a tumor is growing, mitotic activity is reported as both a count and an index, across all carcinoma cells on the slide.
  • Nerve and fat: HETA's tissue segmentation now identifies nerve and fat, for a total of 9 classes. Tumor invasion of both tissues is linked to prognosis, and nerve segmentation is the basis for future perineural invasion readouts.

Also in This Update

HETA's readouts now extend to tumor-stroma ratio, necrosis coverage, desmoplasia (fibroblast density in tumor stroma), and nuclear morphometry. Tumor-stroma ratio is relevant for antibody-drug conjugate (ADC) programs, where dense stroma can limit payload delivery. Improved tumor zones delineate invasive margins and necrosis more accurately.

Get Started

HETA outputs come as overlays in the Aignostics pathology viewer or your own image management system, plus exportable quantitative readouts. All life sciences customers are eligible for a free trial of HETA, and HETA validation metrics are available on request.

‍

Forr research use only. Not for use in diagnostic procedures.